Results 101 to 110 of about 4,120,724 (290)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Creative Commons

open access: yes, 2015
Was sind freie Inhalte, wo findet man sie, wie funktionieren die verschiedenen Creative-Commons-Lizenzen? Das iRights.info-Dossier bündelt ausgewählte Artikel und Veröffentlichungen zur Einführung, zu speziellen Fragen sowie zu Mythen, Mühen und Erfolgen bei freien Lizenzen.
openaire   +2 more sources

Common Creativity International: CC-licensing and Other Options for TEI-based Digital Editions in an International Context

open access: yesJournal of the Text Encoding Initiative, 2019
In the digital age, the legal situation of the data produced in research projects that are relevant to an international research community such as the TEI is becoming more and more important.
Vanessa Hannesschläger
doaj   +1 more source

Model Rules for a FairShares Cooperative (v3.0f) [PDF]

open access: yes
Model Rules for an FCA Accepted FairShares Cooperative Version 3.0f, 12th October 2018 The FairShares Model was licensed to the FairShares Association under a Creative Commons Licence by Rory Ridley-Duff and Cliff Southcombe.
Ridley-Duff, Rory   +2 more
core  

Measuring organisational readiness for patient engagement (MORE) : an international online Delphi consensus study [PDF]

open access: yes, 2015
Date of Acceptance: 28/01/2015. © 2015 Oostendorp et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits ...
A Coulter   +35 more
core   +3 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

A SOCIABILIZAÇÃO DA TV DIGITAL BRASILEIRA: O CREATIVE COMMONS COMO POTENCIAL INSTRUMENTO DE EDUCAÇÃO E DESENVOLVIMENTO LOCAL

open access: yesRevista Direitos Culturais, 2018
Com o advento do Sistema Brasileiro de Televisão Digital (SBTVD), iniciaram-se testes de funcionalidade para os sistemas híbridos que integram a radiodifusão e a internet, possibilitando a criação de conteúdos digitais tanto pelas emissoras, quanto pelos
Lúcio Marcos Do Bom Conselho   +1 more
doaj   +1 more source

Creative Commons

open access: yesTelecommunications Journal of Australia, 2010
This paper written by one of the Creative Commons project leaders for Australia outlines the background and operation of Creative Commons (CC) licensing which has emerged as a new form of copyright management for the Web 2.0 era. It documents examples of how CC licensing is being used including the recent adoption of it by government departments.
openaire   +3 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy